Asia-Pacific Human Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers the Asia-Pacific Human Insulin Market by Company and It is Segmented Into Product Type (Basal or Long - Acting Insulin, Bolus or Fast Acting Insulin, Traditional Human Insulin, Biosimilar Insulin, and Combination Insulin) and by Asia-Pacific. The Market Provides the Value (in USD) and Volume (in Ml) for the Above-Mentioned Segments.

Asia-Pacific Human Insulin Market Size

Asia - Pacific Human Insulin Market Summary

Asia-Pacific Human Insulin Market Analysis

The Asia - Pacific Human Insulin Market size is estimated at USD 7.67 billion in 2025, and is expected to reach USD 8.69 billion by 2030, at a CAGR of 2.54% during the forecast period (2025-2030).

During the COVID-19 crisis, the Asia-Pacific diabetes market saw a gradual growth in demand for diabetic medications. According to a 2021 BeatO research on 800 participants, patients with COVID-19 and pre-existing diabetes suffered blood glucose level changes, resulting in a significant need for advanced diabetic medicines. To mitigate the disastrous impact of COVID-19, Novo Nordisk established a new social responsibility plan to combat diabetes, intending to provide patients in every nation with access to affordable diabetic care.

Diabetes patients, particularly those with Type 2 diabetes, have increased rapidly in Asian nations during the last few decades. Developing nations account for more than 70% of the worldwide diabetes population. The Asia-Pacific region is expected to develop significantly due to an aging population and rising diabetes prevalence, mostly due to increased stress, sedentary lifestyles, smoking, and excessive alcohol intake, which raises the body's sugar levels. Furthermore, the region's production base of key anti-diabetic medicine businesses aided market expansion. However, one of the primary constraining factors for the industry is the rising cost of pharmaceuticals.

The genetic factor is one of the primary reasons for the rapid spread of the disease. Sedentary lifestyles and obesity are the other factors responsible for the high prevalence of the disease. Although insulin has been used for treating diabetes for over 90 years, more than half of those who need insulin today still cannot afford and access it due to the high cost of the product.

Asia-Pacific Human Insulin Industry Overview

The Asia-Pacific Human Insulin Market is highly consolidated, with three major manufacturers having a large market share. However, many local companies have brought biosimilar insulin at a much lower price. Mergers and acquisitions between the players in the recent past helped the companies strengthen their market presence. Sandoz partnered with Gan&Lee for the commercialization of insulin developed by Gan&Lee. Sandoz will likely fully commercialize these medicines in the EU, the United States, Switzerland, Japan, South Korea, Canada, Australia, and New Zealand.

Asia-Pacific Human Insulin Market Leaders

  1. Novo Nordisk

  2. Eli Lilly

  3. Sanofi

  4. Biocon

  5. Gan & Lee

  6. *Disclaimer: Major Players sorted in no particular order
Asia - Pacific Human Insulin Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Asia-Pacific Human Insulin Market News

  • September 2023: Meitheal Pharmaceuticals has secured the exclusive licensing rights from Tonghua Dongbao Pharmaceutical, a China-based company, to distribute three insulin biosimilars in the United States. These biosimilars consist of two rapid-acting insulins, insulin lispro and insulin aspart, as well as the long-acting insulin glargine. The parent company of Meitheal, Nanjing King-Friend Biochemical Pharmaceutical, has acquired these rights.
  • March 2023: About three months after its approval for diabetes treatment, Hangzhou Zhongmei Huadong Pharma's Liraglutide Injection (Liluping) was also given the green light for obesity care.

Asia-Pacific Human Insulin Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Drug
    • 5.1.1 Insulin
    • 5.1.1.1 Basal or Long Acting Insulins
    • 5.1.1.1.1 Lantus (Insulin Glargine)
    • 5.1.1.1.2 Levemir (Insulin Detemir)
    • 5.1.1.1.3 Toujeo (Insulin Glargine)
    • 5.1.1.1.4 Tresiba (Insulin Degludec)
    • 5.1.1.1.5 Abasaglar (Insulin Glargine)
    • 5.1.1.2 Bolus or Fast Acting Insulins
    • 5.1.1.2.1 NovoRapid/Novolog (Insulin Aspart)
    • 5.1.1.2.2 Humalog (Insulin Lispro)
    • 5.1.1.2.3 Apidra (Insulin Glulisine)
    • 5.1.1.2.4 FIASP (Insulin Aspart)
    • 5.1.1.2.5 Admelog (Insulin Lispro)
    • 5.1.1.3 Traditional Human Insulins
    • 5.1.1.3.1 Novolin/Actrapid/Insulatard
    • 5.1.1.3.2 Humilin
    • 5.1.1.3.3 Insuman
    • 5.1.1.4 Insulin Combinations
    • 5.1.1.4.1 NovoMix (Biphasic Insulin Aspart)
    • 5.1.1.4.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    • 5.1.1.4.3 Xultophy (Insulin Degludec and Liraglutide)
    • 5.1.1.4.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
    • 5.1.1.5 Biosimilar Insulins
    • 5.1.1.5.1 Insulin Glargine Biosimilars
    • 5.1.1.5.2 Human Insulin Biosimilars
  • 5.2 Geography
    • 5.2.1 Australia
    • 5.2.2 China
    • 5.2.3 India
    • 5.2.4 Indonesia
    • 5.2.5 Japan
    • 5.2.6 Malaysia
    • 5.2.7 Philippines
    • 5.2.8 South Korea
    • 5.2.9 Thailand
    • 5.2.10 Vietnam
    • 5.2.11 Rest of Asia-Pacific

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetic Population
  • 6.2 Type-2 Diabetic Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Eli Lilly
    • 7.1.3 Sanofi
    • 7.1.4 Biocon
    • 7.1.5 Gan & Lee
    • 7.1.6 Wockhardt
  • *List Not Exhaustive
  • 7.2 Company Share Analysis
    • 7.2.1 Novo Nordisk
    • 7.2.2 Eli Lilly
    • 7.2.3 Sanofi
    • 7.2.4 Other Companies

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products andĀ Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Asia-Pacific Human Insulin Industry Segmentation

Regular insulin is a kind of medical short-acting insulin, sometimes referred to as neutral and soluble insulin. Type 1 diabetes, Type 2 diabetes, gestational diabetes, and diabetic complications such as diabetic ketoacidosis and hyperosmolar hyperglycemic states are all treated with it. Asia-Pacific Human Insulin Market is segmented into Product Type and by Asia-Pacific. The market provides the value (in USD) and Volume (in ml) for the above-mentioned segments.

Drug Insulin Basal or Long Acting Insulins Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Abasaglar (Insulin Glargine)
Bolus or Fast Acting Insulins NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
FIASP (Insulin Aspart)
Admelog (Insulin Lispro)
Traditional Human Insulins Novolin/Actrapid/Insulatard
Humilin
Insuman
Insulin Combinations NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
Biosimilar Insulins Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography Australia
China
India
Indonesia
Japan
Malaysia
Philippines
South Korea
Thailand
Vietnam
Rest of Asia-Pacific
Need A Different Region or Segment?
Customize Now

Asia-Pacific Human Insulin Market Research FAQs

How big is the Asia - Pacific Human Insulin Market?

The Asia - Pacific Human Insulin Market size is expected to reach USD 7.67 billion in 2025 and grow at a CAGR of 2.54% to reach USD 8.69 billion by 2030.

What is the current Asia - Pacific Human Insulin Market size?

In 2025, the Asia - Pacific Human Insulin Market size is expected to reach USD 7.67 billion.

Who are the key players in Asia - Pacific Human Insulin Market?

Novo Nordisk, Eli Lilly, Sanofi, Biocon and Gan & Lee are the major companies operating in the Asia - Pacific Human Insulin Market.

What years does this Asia - Pacific Human Insulin Market cover, and what was the market size in 2024?

In 2024, the Asia - Pacific Human Insulin Market size was estimated at USD 7.48 billion. The report covers the Asia - Pacific Human Insulin Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Asia - Pacific Human Insulin Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Asia-Pacific Human Insulin Industry Report

Statistics for the 2025 Asia - Pacific Human Insulin market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Asia - Pacific Human Insulin analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Asia-Pacific Human Insulin Market Report Snapshots

Compare market size and growth of Asia - Pacific Human Insulin Market with other markets in Healthcare Industry

Asia-Pacific Human Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)